Live Breaking News & Updates on Vnda

Stay updated with breaking news from Vnda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 16.9% in April

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 2,070,000 shares, a decline of 16.9% from the March 31st total of 2,490,000 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 0.9 […]

Switzerland , China , Ohio , United-states , Swiss , Swiss-national-bank , China-universal-asset-management-co , Vanda-pharmaceuticals , Nasdaq , Vanda-pharmaceuticals-price-performance , News-ratings-for-vanda-pharmaceuticals-daily

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 16.9% in April

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,070,000 shares, a drop of 16.9% from the March 31st total of 2,490,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the days-to-cover […]

Los-angeles , California , United-states , Vanda-pharmaceuticals-inc , Jacobs-levy-equity-management-inc , Nasdaq , Stonepine-capital-management , Capital-partners , Acadian-asset-management , Vanda-pharmaceuticals-company-profile , News-ratings-for-vanda-pharmaceuticals-daily

Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a buy rating to a hold rating in a report issued on Monday. Separately, TheStreet lowered Vanda Pharmaceuticals from a c- rating to a d rating in a research note on Thursday, February 8th. View Our Latest Analysis on VNDA Vanda Pharmaceuticals Price Performance […]

China , New-york , United-states , Switzerland , Swiss , Nasdaq , Vanda-pharmaceuticals-price-performance , News-ratings-for-vanda-pharmaceuticals-daily , Institutional-investors-weigh-in-on-vanda-pharmaceuticals , China-universal-asset-management-co , Vanda-pharmaceuticals-inc

Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a hold rating to a buy rating in a report issued on Thursday. Vanda Pharmaceuticals Stock Performance Vanda Pharmaceuticals stock opened at $3.76 on Thursday. The firm has a market cap of $216.31 million, a price-to-earnings ratio of 17.91 and a beta of 0.59. […]

Lido-advisors , Sherbrooke-park-advisers , Tower-research-capital , Quadrant-capital-group , Vanda-pharmaceuticals , Vanda-pharmaceuticals-inc , Vanda-pharmaceuticals-company-profile , Vanda-pharmaceuticals-stock-performance , News-ratings-for-vanda-pharmaceuticals-daily , Free-report , Capital-group

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 1,510,000 shares, a decline of 64.1% from the September 15th total of 4,210,000 shares. Currently, 3.1% of the company’s stock are short sold. Based on an […]

Stephen-ray-mitchell , Vanda-pharmaceuticals-company-profile , Nasdaq , Renaissance-technologies , Vanda-pharmaceuticals , Securities-exchange-commission , Hedge-funds-weigh-in-on-vanda-pharmaceuticals , News-ratings-for-vanda-pharmaceuticals-daily , Vanda-pharmaceuticals-stock-performance , Dimensional-fund-advisors , Vanguard-group-inc , Blackrock-inc

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 50.4% in September

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 4,210,000 shares, a growth of 50.4% from the August 31st total of 2,800,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio […]

Stephen-ray-mitchell , Lazard-asset-management , Financial-services-group-inc , Insider-activity-at-vanda-pharmaceuticals , Vanda-pharmaceuticals-inc , News-ratings-for-vanda-pharmaceuticals-daily , Quadrant-capital-group , Nasdaq , Securities-exchange-commission , Vanda-pharmaceuticals , Tower-research-capital , Vanda-pharmaceuticals-trading-down

Profit Investment Management LLC Cuts Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Profit Investment Management LLC lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 1.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 328,668 shares of the biopharmaceutical company’s stock after selling 4,195 shares during the period. Vanda Pharmaceuticals […]

Stephen-ray-mitchell , Panagora-asset-management-inc , Yousif-capital-management , Commonwealth-of-pennsylvania-public-school-empls-retrmt , Securities-exchange-commission , Vanda-pharmaceuticals-inc , Vanda-pharmaceuticals-price-performance , Exchange-commission , Metlife-investment-management , News-ratings-for-vanda-pharmaceuticals-daily , Jpmorgan-chase-co , Quarter-for-vanda-pharmaceuticals

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research note issued to investors on Thursday. The firm issued a buy rating on the biopharmaceutical company’s stock. Vanda Pharmaceuticals Trading Up 0.2 % NASDAQ:VNDA opened at $5.85 on Thursday. Vanda Pharmaceuticals has a 1 year low of $5.45 and a […]

Kevin-patrick-moran , Timothy-williams , Quadrant-capital-group , Capital-advisors-ltd , Vanda-pharmaceuticals-inc , Lazard-asset-management , News-ratings-for-vanda-pharmaceuticals-daily , Nasdaq , Vanda-pharmaceuticals , Vanda-pharmaceuticals-trading , Hedge-funds-weigh-in-on-vanda-pharmaceuticals , Tower-research-capital